Affordable Access

Infusion Product TNFα, Th2, and STAT3 Activities Are Associated with Clinical Responses to Transgenic T-cell Receptor Cell Therapy

Authors
  • Nowicki, Theodore S
  • Peters, Cole W
  • Quiros, Crystal
  • Kidd, Conner K
  • Kawakami, Moe
  • Klomhaus, Alexandra M
  • Baselga-Carretero, Ignacio
  • Kaplan-Lefko, Paula
  • Macabali, Mignonette H
  • Garcilazo, Ivan Perez
  • Berent-Maoz, Beata
  • Comin-Anduix, Begoña
  • Ribas, Antoni
Publication Date
Dec 01, 2023
Source
eScholarship - University of California
Keywords
License
Unknown
External links

Abstract

Transgenic T-cell receptor (TCR) T cell-based adoptive cell therapies for solid tumors are associated with dramatic initial response rates, but there remain many instances of treatment failure and disease relapse. The association of infusion product cytokine profiles with clinical response has not been explored in the context of TCR T-cell therapy products. Single-cell antigen-dependent secretomic and proteomic analysis of preinfusion clinical TCR T-cell therapy products revealed that TNFα cytokine functionality of CD8+ T cells and phospho-STAT3 signaling in these cells were both associated with superior clinical responsiveness to therapy. By contrast, CD4+ T-helper 2 cell cytokine profiles were associated with inferior clinical responses. In parallel, preinfusion levels of IL15, Flt3-L, and CX3CL1 were all found to be associated with clinical response to therapy. These results have implications for the development of therapeutic biomarkers and identify potential targets for enrichment in the design of transgenic TCR T-cell therapies for solid tumors.

Report this publication

Statistics

Seen <100 times